The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
70
Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
One single dose of 40 mg. Tablet
Novo Nordisk Investigational Site
Uppsala, Sweden
Area under the curve of atorvastatin
Area under the curve of lisinopril
Area under the curve of griseofulvin
Area under the curve of digoxin
Area under the curve of liraglutide
Cmax, maximum concentration
tmax, time to reach Cmax
Terminal elimination rate constant
Intragastric pH
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
One single dose of 20 mg. Tablet
One single dose of 500 mg. Tablet
One single dose of 1 mg. Tablet